Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Bucay, N.; Sarosi, I.; Dunstan, C. R.; Morony, S.; Tarpley, J.; Capparelli, C.; Scully, S.; Tan, H. L.; Xu, W.; Lacey, D. L.; Boyle, W. J.; Simonet, W. S.

doi:10.1101/gad.12.9.1260

Cited by 2,483Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Open access

Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L. +4 more·1998·Genes & Development

DOI 10.1101/gad.12.9.1260PMC PMC316769

Open this paper in CoChat — free account Open PDF

Abstract

Osteoprotegerin (OPG) is a secreted protein that inhibits osteoclast formation. In this study the physiological role of OPG is investigated by generating OPG-deficient mice. Adolescent and adult OPG-/- mice exhibit a decrease in total bone density characterized by severe trabecular and cortical bone porosity, marked thinning of the parietal bones of the skull, and a high incidence of fractures. These findings demonstrate that OPG is a critical regulator of postnatal bone mass. Unexpectedly, OPG-deficient mice also exhibit medial calcification of the aorta and renal arteries, suggesting that regulation of OPG, its signaling pathway, or its ligand(s) may play a role in the long observed association between osteoporosis and vascular calcification.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.12.9.1260

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Mice overexpressing OPG get osteopetrosis, while OPG-knockout mice get severe osteoporosis and frequent fractures.
“overexpression of OPG produced osteopetrosis, while OPG-knockout mice had a phenotype of severe osteoporosis with a high incidence of fractures”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [46]
OPG knockout mice have severe osteopenia with increased bone turnover, cortical porosity, reduced cortical and cancellous bone volume and density, and spontaneous fragility fractures in early life.
“The essential physiological role of OPG in maintaining bone mass was shown by the severe osteopenic phenotype of OPG knockout mice (124 -126).These mice exhibit increased bone turnover, cortical porosity, and reductions in cortical and cancellous bone volume and density.These deleterious changes are accompanied by spontaneous fragility fractures in the first weeks of life (124).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [124]
OPG knockout animals develop medial calcification of the aorta and renal arteries along with elevated bone turnover.
“OPG knockout animals developed medial calcification of the aorta and renal arteries, in association with elevated bone turnover (124).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [124]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works
Self-citation
Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein
Luo, G., Ducy, P. F., McKee, M. D., Pinero, G. J., Loyer, E. M., Behringer, R. R., & Karsenty, G. (1997) · Nature · doi:10.1038/386078a0 · Cited by 2,118 · see citing works
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P. M., Montgomery, C. A., Geske, R. S., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 1,997 · see citing works
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., Shultz, L. D., & Nishikawa, S.-I. (1990) · Nature · doi:10.1038/345442a0 · Cited by 1,789 · see citing works
Bone Marrow, Cytokines, and Bone Remodeling — Emerging Insights into the Pathophysiology of Osteoporosis
Manolagas, S. C., & Jilka, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320506 · Cited by 1,684 · see citing works
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B. F., Broxmeyer, H. E., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,440 · see citing works
Bone morphogenetic protein expression in human atherosclerotic lesions.
Boström, K. I., Watson, K. E., Horn, S. E. V., Wortham, C., Herman, I. M., & Demer, L. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116391 · Cited by 1,020 · see citing works
OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION
Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-123-5-2600 · Cited by 934 · see citing works
Bone and haematopoietic defects in mice lacking c-fos
Wang, Z., Ovitt, C. E., Grigoriadis, A. E., Möhle-Steinlein, U., Rüther, U., & Wagner, E. F. (1992) · Nature · doi:10.1038/360741a0 · Cited by 932 · see citing works
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β
Hughes, D. E., Dai, A., Tiffee, J. C., Li, H. H., Mundy, G. R., & Boyce, B. F. (1996) · Nature Medicine · doi:10.1038/nm1096-1132 · Cited by 813 · cited 1× · see citing works
“Some systemic and local factors that regulate development and interplay between osteoclasts and osteoblasts have been identified (Mundy 1993a,b; Erlebacher and Derynck 1996; Manolagas and Jilka 1995; Hughes et al. 1996; Pacifici 1996).”
Background
Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis
Pacifici, R. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110802 · Cited by 741 · see citing works
Toward a molecular understanding of skeletal development
Erlebacher, A., Filvaroff, E. H., Gitelman, S. E., & Derynck, R. (1995) · Cell · doi:10.1016/0092-8674(95)90487-5 · Cited by 683 · see citing works
Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques.
Giachelli, C. M., Bae, N., de Almeida, M. A. G., Denhardt, D. T., Alpers, C. E., & Schwartz, S. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116755 · Cited by 641 · see citing works
Genetic variability in adult bone density among inbred strains of mice
Beamer, W. G., Donahue, L. R., Rosen, C. J., & Baylink, D. J. (1996) · Bone · doi:10.1016/8756-3282(96)00047-6 · Cited by 630 · see citing works
Lipid Oxidation Products Have Opposite Effects on Calcifying Vascular Cell and Bone Cell Differentiation: A Possible Explanation for the Paradox of Arterial Calcification in Osteoporotic Patients
Parhami, F., Morrow, A. D., Balucan, J., Leitinger, N., Watson, A. D., Tintut, Y., Berliner, J. A., & Demer, L. L. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.4.680 · Cited by 619 · see citing works
Advances in Bone Biology: The Osteoclast*
Roodman, G. D. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-4-308 · Cited by 553 · see citing works
Osteopontin Is Expressed in Human Aortic Valvular Lesions
O’Brien, K. D., Kuusisto, J., Reichenbach, D. D., Ferguson, M. S., Giachelli, C. M., Alpers, C. E., & Otto, C. M. (1995) · Circulation · doi:10.1161/01.cir.92.8.2163 · Cited by 441 · see citing works
Interleukin-11: a new cytokine critical for osteoclast development.
Girasole, G., Passeri, G., Jilka, R. L., & Manolagas, S. C. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117130 · Cited by 395 · see citing works
Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype.
Erlebacher, A., & Derynck, R. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.132.1.195 · Cited by 371 · see citing works
Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice.
Kitazawa, R., Kimble, R. B., Vannice, J. L., Kung, V. T., & Pacifici, R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117606 · Cited by 336 · see citing works
Role of cytokines in bone resorption
Manolagas, S. C. (1995) · Bone · doi:10.1016/8756-3282(95)00180-l · Cited by 315 · see citing works
Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo.
de la Mata, J., Uy, H., Guise, T. A., Story, B. M., Boyce, B. F., Mundy, G. R., & Roodman, G. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117990 · Cited by 254 · see citing works
Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification.
Qiao, J. H., Xie, P. Z., Fishbein, M. C., Kreuzer, J., Drake, T. A., Demer, L. L., & Lusis, A. J. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.9.1480 · Cited by 239 · see citing works
Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta
Schmid, K., McSharry, W. O., Pameijer, C. H., et al. (1980) · Atherosclerosis · doi:10.1016/0021-9150(80)90005-2 · Cited by 189 · see citing works
Journal of Bone and Mineral Research
Mundy, G. R. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081315 · Cited by 173 · see citing works
Osteoporosis induced in mice by overproduction of interleukin 4.
Lewis, D. B., Liggitt, H. D., Effmann, E. L., Motley, S. T., Teitelbaum, S. L., Jepsen, K. J., Goldstein, S. A., Bonadio, J. F., Carpenter, J., & Perlmutter, R. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11618 · Cited by 165 · see citing works
Effect of degenerative spinal and aortic calcification on bone density measurements in post‐menopausal women: links between osteoporosis and cardiovascular disease?
Banks, L. M., Lees, B., MacSweeney, J. E., et al. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb02024.x · Cited by 165 · see citing works
A Skeleton in the Atherosclerosis Closet
Demer, L. L. (1995) · Circulation · doi:10.1161/01.cir.92.8.2029 · Cited by 149 · see citing works
The effects of cytokines and growth factors on osteoblastic cells
Mundy, G. R., Boyce, B. F., Hughes, D. E., et al. (1995) · Bone · doi:10.1016/8756-3282(95)00182-d · Cited by 141 · see citing works
Atherosclerotic calcification: Relation to developmental osteogenesis
Boström, K. I., Watson, K. E., Stanford, W. P., et al. (1995) · The American Journal of Cardiology · doi:10.1016/0002-9149(95)80020-s · Cited by 114 · see citing works
Advances in bone biology: the osteoclast
Roodman, G. D. (1996) · Endocrine Reviews · doi:10.1210/er.17.4.308 · Cited by 110 · see citing works
Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages
Lacey, D. L., Erdmann, J. M., Teitelbaum, S. L., Tan, H., Ohara, J., & Shioi, A. (1995) · Endocrinology · doi:10.1210/endo.136.6.7750457 · Cited by 87 · see citing works
Self-citation
Targeted disruption of the c-src protooncogene leads to osteopetrosis in mice
(1991) · Trends in Cell Biology · doi:10.1016/0962-8924(91)90049-f · Cited by 87 · see citing works
Role of cytokines in bone resorption
Mundy, G. R. (1993) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240530405 · Cited by 79 · see citing works
The murine mutation osteopetrosis is in the coding region of the macrophage colony-stimulating factor gene
(1990) · Trends in Genetics · doi:10.1016/0168-9525(90)90199-g · Cited by 73 · see citing works
Overexpression of the granulocyte colony-stimulating factor gene leads to osteoporosis in mice.
Takahashi, T., Wada, T., Mori, M., et al. (1996) · PubMed · Cited by 67 · see citing works
THE FORMATION OF TRUE BONE WITH CELLULAR (RED) MARROW IN A SCLEROTIC AORTA
Bunting, C. H. (1906) · The Journal of Experimental Medicine · doi:10.1084/jem.8.3.365 · Cited by 59 · see citing works
Arterial calcification in face of osteoporosis in ageing: can we blame oxidized lipids?
Parhami, F., & Demer, L. L. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199710000-00010 · Cited by 51 · see citing works
Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo.
Uy, H., Guise, T. A., Mata, J. D. L., et al. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628353 · Cited by 43 · see citing works
Role of Molecular Regulation in Vascular Calcification
Parhami, F., m, K. B. O., Watson, K. E., et al. (1996) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.3.90 · Cited by 43 · see citing works
Mechanism of calcification in spontaneous aortic arteriosclerotic lesions of the rabbit. An electron microscopic study.
HAUST, M. D., & Geer, J. C. (1970) · PubMed Central · Cited by 38 · see citing works
Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo
Uy, H. (1995) · Endocrinology · doi:10.1210/en.136.8.3207 · Cited by 22 · see citing works

Flagged first, then by citations

Sorted by citations

Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · see citing works
Self-citation
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793 · see citing works
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844 · see citing works
Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779 · see citing works
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636 · see citing works
Self-citation
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478 · see citing works
Chronic Kidney Disease: Effects on the Cardiovascular System
Schiffrin, E. L., Lipman, M. L., & Mann, J. F. E. (2007) · Circulation · doi:10.1161/circulationaha.106.678342 · Cited by 1,448 · see citing works
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · see citing works
Disorders of Bone Remodeling
Feng, X., & McDonald, J. M. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130203 · Cited by 1,272 · see citing works
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism.
Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119 · see citing works
Self-citation
Skeletal remodeling in health and disease
Zaidi, M. (2007) · Nature Medicine · doi:10.1038/nm1593 · Cited by 1,069 · see citing works
Pathogenesis of bone fragility in women and men
Seeman, E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08706-8 · Cited by 909 · see citing works
The aging of the immune system
Weiskopf, D., Weinberger, B., & Grubeck-Loebenstein, B. (2009) · Transplant International · doi:10.1111/j.1432-2277.2009.00927.x · Cited by 908 · see citing works
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works
Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · see citing works
Self-citation
The aging of Wolff’s “law”: Ontogeny and responses to mechanical loading in cortical bone
Pearson, O. M., & Lieberman, D. E. (2004) · American Journal of Physical Anthropology · doi:10.1002/ajpa.20155 · Cited by 745 · see citing works
RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis
Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., Morinaga, T., & Higashio, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9788 · Cited by 746 · see citing works
OSTEOIMMUNOLOGY: Interplay Between the Immune System and Bone Metabolism
Walsh, M. C., Kim, N., Kadono, Y., Rho, J., Lee, S. Y., Lorenzo, J., & Choi, Y. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090646 · Cited by 724 · see citing works
Apoptosis Regulates Human Vascular Calcification In Vitro: Evidence for Initiation of Vascular Calcification by Apoptotic Bodies
Proudfoot, D., Skepper, J. N., Hegyi, L., Bennett, M. R., Shanahan, C. M., & Weissberg, P. L. (2000) · Circulation Research · doi:10.1161/01.res.87.11.1055 · Cited by 719 · see citing works
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α
Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., & Pacifici, R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11066 · Cited by 705 · see citing works
Calcific Aortic Stenosis
Dweck, M. R., Boon, N. A., & Newby, D. E. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.093 · Cited by 692 · see citing works
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689 · see citing works
Self-citation
Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus
Yahagi, K., Kolodgie, F. D., Lutter, C., Mori, H., Romero, M. E., Finn, A. V., & Virmani, R. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306256 · Cited by 573 · see citing works
Biology of the RANKLâ€“RANKâ€“OPG System in Immunity, Bone, and Beyond
Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599 · see citing works
Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586 · see citing works
Expression of osteoprotegerin, receptor activator of NF-κB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon, T., Cho, T.-J., Aizawa, T., Yamazaki, M., Nooh, N., Graves, D., Gerstenfeld, L. C., & Einhorn, T. A. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.6.1004 · Cited by 552 · see citing works
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.
Min, H., Morony, S., Sarosi, I., Dunstan, C. R., Capparelli, C., Scully, S., Van, G., Kaufman, S., Kostenuik, P. J., Lacey, D. L., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.463 · Cited by 550 · see citing works
Self-citation
Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1
Thomas, R. J., Guise, T. A., Yin, J. J., Elliott, J., Horwood, N. J., Martin, T. J., & Gillespie, M. T. (1999) · Endocrinology · doi:10.1210/endo.140.10.7037 · Cited by 536 · see citing works
Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.
Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein, J., & Choi, Y. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201394498 · Cited by 518 · see citing works
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo
Li, Y., Toraldo, G., Li, A., Yang, X., Zhang, H., Qian, W.-P., & Weitzmann, M. N. (2007) · Blood · doi:10.1182/blood-2006-07-037994 · Cited by 520 · see citing works
Regulation of Osteoclast Differentiation by Cytokine Networks
Amarasekara, D. S., Yun, H., Kim, S., Lee, N., Kim, H., & Rho, J. (2018) · Immune Network · doi:10.4110/in.2018.18.e8 · Cited by 518 · see citing works
Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption
Sims, N. A., & Gooi, J. H. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.016 · Cited by 513 · see citing works
Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo
Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., & Pacifici, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251534698 · Cited by 513 · see citing works
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · see citing works
Self-citation
Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee, S.-K., & Lorenzo, J. A. (1999) · Endocrinology · doi:10.1210/endo.140.8.6887 · Cited by 464 · see citing works
The role of NFAT in osteoclast formation
TAKAYANAGI, H. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.071 · Cited by 442 · see citing works
Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428 · see citing works
RANK/RANKL: Regulators of Immune Responses and Bone Physiology
Leibbrandt, A., & Penninger, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.016 · Cited by 420 · see citing works
Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment
Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415 · see citing works
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413 · see citing works
Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis
Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., & Osdoby, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010153200 · Cited by 398 · see citing works
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.
Price, P. A., June, H. H., Buckley, J. R., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1001.097102 · Cited by 376 · see citing works
Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis
Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W. M., Ryan, P. F. J., Dunstan, C. R., Martin, T. J., & Gillespie, M. T. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64417-3 · Cited by 368 · see citing works
Self-citation
Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · see citing works
The RANKL/RANK/OPG pathway
Boyce, B. F., & Xing, L. (2007) · Current Osteoporosis Reports · doi:10.1007/s11914-007-0024-y · Cited by 339 · see citing works
The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts.
Bord, S., Ireland, D. C., Beavan, S. R., & Compston, J. E. (2003) · Bone · doi:10.1016/s8756-3282(02)00953-5 · Cited by 333 · see citing works
MLO-Y4 Osteocyte-Like Cells Support Osteoclast Formation and Activation
Zhao, S., Kato, Y., Zhang, Y., Harris, S., Ahuja, S. S., & Bonewald, L. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.11.2068 · Cited by 322 · see citing works
RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling
Tobeiha, M., Moghadasian, M. H., Amin, N., & Jafarnejad, S. (2020) · BioMed Research International · doi:10.1155/2020/6910312 · Cited by 309 · see citing works
OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40.
Yun, T. J., Chaudhary, P. M., Shu, G. L., Frazer, J. K., Ewings, M. K., Schwartz, S. M., Pascual, V., Hood, L. E., & Clark3, E. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6113 · Cited by 307 · see citing works
Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE −/− Mice
Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000236428.91125.e6 · Cited by 304 · see citing works
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
Price, P. A., Faus, S. A., & Williamson, M. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.5.817 · Cited by 301 · see citing works
Molecular and cellular biology of alveolar bone
SODEK, J., & MCKEE, M. D. (2000) · Periodontology 2000 · doi:10.1034/j.1600-0757.2000.2240106.x · Cited by 283 · see citing works
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281 · see citing works
Regulation of TNF-Induced Osteoclast Differentiation
Yao, Z., Getting, S. J., & Locke, I. C. (2021) · Cells · doi:10.3390/cells11010132 · Cited by 280 · see citing works
“Thus, genetic deletion of OPG leads to osteoporosis in mice [77,78], and homozygous deletion of 100 kilobases of OPG gene in human results in juvenile Paget’s disease, characterized by osteopenia and fractures [79].”
Background
Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr (−/−) Mice
Morony, S., Tintut, Y., Zhang, Z., Cattley, R. C., Van, G., Dwyer, D., Stolina, M., Kostenuik, P. J., & Demer, L. L. (2008) · Circulation · doi:10.1161/circulationaha.107.707380 · Cited by 258 · see citing works
Self-citation
Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells
Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251 · see citing works
Inflammatory osteolysis: A conspiracy against bone
Mbalaviele, G., Novack, D. V., Schett, G., & Teitelbaum, S. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93356 · Cited by 251 · see citing works
Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-κB ligand.
Hikita, A., Yana, I., Wakeyama, H., Nakamura, M., Kadono, Y., Oshima, Y., Nakamura, K., Seiki, M., & Tanaka, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606656200 · Cited by 236 · see citing works
Osteoporosis: Mechanism, Molecular Target and Current Status on Drug Development
Li, H., Xiao, Z., Quarles, L. D., & Li, W. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200330142432 · Cited by 226 · see citing works
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215 · see citing works
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint
Haynes, D. R., Crotti, T. N., Loric, M., Bain, G. I., Atkins, G. J., & Findlay, D. M. (2001) · Rheumatology · doi:10.1093/rheumatology/40.6.623 · Cited by 216 · see citing works
RANKL/OPG; Critical role in bone physiology
Martin, T. J., & Sims, N. A. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9308-6 · Cited by 213 · see citing works
Correlates of osteoprotegerin levels in women and men.
Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205 · see citing works
Self-citation
High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment.
Ziolkowska, M., Kurowska, M., Radzikowska, A., Luszczykiewicz, G., Wiland, P., Dziewczopolski, W., Filipowicz‐Sosnowska, A., Pazdur, J., Szechinski, J., Kowalczewski, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10388 · Cited by 200 · see citing works
Characterization of Regulatory Extracellular Vesicles from Osteoclasts
Huynh, N., VonMoss, L., Smith, D., Rahman, I., Felemban, M. F., Zuo, J., Rody, W. J., McHugh, K. P., & Holliday, L. S. (2016) · Journal of Dental Research · doi:10.1177/0022034516633189 · Cited by 196 · see citing works
17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α.
Saika, M., Inoue, D., Kido, S., & Matsumoto, T. (2001) · Endocrinology · doi:10.1210/endo.142.6.8220 · Cited by 194 · see citing works
Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function.
Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. K., Mohaupt, M., Herring, S. W., & Clark, E. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1482 · Cited by 195 · see citing works
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Nakamura, M., Udagawa, N., Matsuura, S., Mogi, M., Nakamura, H., Horiuchi, H., Saito, N., Hiraoka, B. Y., Kobayashi, Y., Takaoka, K., et al. (2003) · Endocrinology · doi:10.1210/en.2003-0717 · Cited by 191 · see citing works
Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.
Crotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M., Tak, P. P., & Haynes, D. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.12.1047 · Cited by 186 · see citing works
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3.
Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187 · see citing works
Self-citation
Serum levels of osteoprotegerin increase with age in a healthy adult population.
Kudlacek, S., Schneider, B., Woloszczuk, W., Pietschmann, P., & Willvonseder, R. (2003) · Bone · doi:10.1016/s8756-3282(03)00090-5 · Cited by 187 · see citing works
Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption
Lamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181 · see citing works
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao, J., Venton, L., Sakata, T., & Halloran, B. P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.270 · Cited by 173 · see citing works
Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice.
Shao, J.-S., Cheng, S.-L., Charlton-Kachigian, N., Loewy, A. P., & Towler, D. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308825200 · Cited by 174 · see citing works
NF-κB p50 and p52 Expression Is Not Required for RANK-Expressing Osteoclast Progenitor Formation but Is Essential for RANK- and Cytokine-Mediated Osteoclastogenesis
Xing, L., Bushnell, T. P., Carlson, L., Tai, Z., Tondravi, M., Siebenlist, U., Young, F., & Boyce, B. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1200 · Cited by 165 · see citing works
Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice: Potential Role of Chondrocyte-Like Cells
Rattazzi, M., Bennett, B. J., Bea, F., Kirk, E. A., Ricks, J. L., Speer, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000166600.58468.1b · Cited by 164 · see citing works
17β-Estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells
Bengtsson, A. K., Ryan, E. J., Giordano, D., Magaletti, D. M., & Clark, E. A. (2004) · Blood · doi:10.1182/blood-2003-10-3380 · Cited by 161 · see citing works
Large animal models of cardiovascular disease
Tsang, H. G., Rashdan, N. A., Whitelaw, C. B. A., Corcoran, B. M., Summers, K. M., & MacRae, V. E. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3173 · Cited by 154 · see citing works
Osteoprotegerin: Multiple partners for multiple functions
Baud’huin, M., Duplomb, L., Teletchea, S., Lamoureux, F., Ruiz-Velasco, C., Maillasson, M., Redini, F., Heymann, M.-F., & Heymann, D. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.06.001 · Cited by 153 · see citing works
Soluble RANKL and risk of nontraumatic fracture.
Schett, G. (2004) · JAMA · doi:10.1001/jama.291.9.1108 · Cited by 146 · see citing works
New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis
Crockett, J. C., Mellis, D. J., Scott, D. I., & Helfrich, M. H. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1272-8 · Cited by 143 · see citing works
The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor κB Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in Osteoarthritis
Fazzalari, N. L., Kuliwaba, J. S., Atkins, G. J., Forwood, M. R., & Findlay, D. M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.6.1015 · Cited by 129 · see citing works
Innate and Adaptive Immunity in Calcific Aortic Valve Disease
Mathieu, P., Bouchareb, R., & Boulanger, M.-C. (2015) · Journal of Immunology Research · doi:10.1155/2015/851945 · Cited by 121 · see citing works
Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie, A., Takami, M., Kubo, H., Sekino-Suzuki, N., Kasahara, K., & Sanai, Y. (2007) · Bone · doi:10.1016/j.bone.2007.04.190 · Cited by 116 · see citing works
New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?
Tat, S. K., Pelletier, J.-P., Velasco, C. R., Padrines, M., & Martel-Pelletier, J. (2009) · The Keio Journal of Medicine · doi:10.2302/kjm.58.29 · Cited by 112 · see citing works
Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
Cawley, K. M., Bustamante-Gomez, N. C., Guha, A. G., MacLeod, R. S., Xiong, J., Gubrij, I., Liu, Y., Mulkey, R., Palmieri, M., Thostenson, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108052 · Cited by 114 · see citing works
Metastatic prostate cancer and the bone: significance and therapeutic options
Gartrell, B. A., Coleman, R., Efstathiou, E., Fizazi, K., Logothetis, C. J., Smith, M. R., Sonpavde, G., Sartor, O., & Saad, F. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.039 · Cited by 101 · see citing works
Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.
Atkins, G. J., Bouralexis, S., Haynes, D. R., Graves, S. E., Geary, S. M., Evdokiou, A., Zannettino, A. C. W., Hay, S., & Findlay, D. M. (2001) · Bone · doi:10.1016/s8756-3282(01)00404-5 · Cited by 105 · see citing works
Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.
Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.5.852 · Cited by 103 · see citing works
Self-citation
RANKL subcellular trafficking and regulatory mechanisms in osteocytes
Honma, M., Ikebuchi, Y., Kariya, Y., Hayashi, M., Hayashi, N., Aoki, S., & Suzuki, H. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1941 · Cited by 98 · see citing works
Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis
Bolon, B., Carter, C., Daris, M., Morony, S., Capparelli, C., Hsieh, A., Mao, M., Kostenuik, P., Dunstan, C. R., Lacey, D. L., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0245 · Cited by 100 · see citing works
Self-citation
Paget’s disease of bone and genetic disorders of RANKL/OPG/RANK/NF-κB signaling.
WHYTE, M. P. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.016 · Cited by 95 · see citing works
The origins and formation of bone-resorbing osteoclasts
Elson, A., Anuj, A., Barnea-Zohar, M., & Reuven, N. (2022) · Bone · doi:10.1016/j.bone.2022.116538 · Cited by 95 · see citing works
Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders
Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91 · see citing works
Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh, K., Udagawa, N., Matsuzaki, K., Takami, M., Amano, H., Shinki, T., Ueno, Y., Takahashi, N., & Suda, T. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.9.1766 · Cited by 90 · see citing works
Bone cell communication factors and Semaphorins
Negishi-Koga, T., & Takayanagi, H. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.183 · Cited by 90 · see citing works
Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis
Zheng, Y., Zhou, H., Brennan, K., Blair, J. M., Modzelewski, J. R. K., Seibel, M. J., & Dunstan, C. R. (2007) · Bone · doi:10.1016/j.bone.2006.09.016 · Cited by 82 · see citing works
Self-citation
Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.
Campagnuolo, G., Bolon, B., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10369 · Cited by 78 · see citing works
Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity
Furuya, Y., Inagaki, A., Khan, M., Mori, K., Penninger, J. M., Nakamura, M., Udagawa, N., Aoki, K., Ohya, K., Uchida, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.426080 · Cited by 77 · see citing works
Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.
Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76 · see citing works

[Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages].
Zhou, X., Liu, Y., Jian, X.-C., et al. (2011) · PubMed · Cited by 1 · see citing works
[Indication of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) in gingival crevicular fluid to remodeling of alveolar bone during retention].
Zhao, N., Lin, J., Chen, Z., et al. (2012) · PubMed · Cited by 1 · see citing works
Different expressing levels of osteoprotegerin and receptor activator of nuclear factor-κB ligand from osteoblasts of young, adult and aged mice
Jian-zhon, H. (2005) · Zhonghua fengshibingxue zazhi
Aging effect of osteoprotegerin and receptor activator of nuclear factor-κB ligand expression in human periodontal ligament cells under continuous static pressure.
Wu, J., Cui, Z., Yu, H., et al. (2022) · PubMed · doi:10.7518/hxkq.2022.06.005 · Cited by 3 · see citing works
EFFECTS OF 1α,25(OH)_2D_3 ON THE EXPRESSION OF RECEPTOR ACTIVATOR OF NF-КB LIGAND AND OSTEOPROTEGERIN IN RAT OSTEOBLASTS IN VITRO
Zong-ping, L. (2010) · Acta Nutrimenta Sinica

Authors: Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., & Simonet, W. S.
Affiliations: Amgen (United States) (US)
ORCID: Dunstan, C. R.
Xu, W.
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 1998-05-01
Volume: 12
Issue: 9
Pages: 1260-1268
ISSN: 0890-9369 (ISSN-L)
DOI: 10.1101/gad.12.9.1260
PMC: PMC316769
OpenAlex: W2129651548
Cited by: 2,483
References: 42
Citations by year: 2026: 29 · 2025: 29 · 2024: 46 · 2023: 43 · 2022: 52 · 2021: 61 · 2020: 90 · 2019: 62 · 2018: 53 · 2017: 93 · 2016: 82 · 2015: 94 · 2014: 89 · 2013: 122 · 2012: 106
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Rheumatology › Bone and Dental Protein Studies
Keywords: osteoprotegerin, osteoporosis, arterial calcification, vascular calcification, osteoclastogenesis, bone mineral density, trabecular bone, cortical bone, bone porosity, fracture, renal artery calcification
MeSH terms: Animals, Arteries, Calcinosis, Disease Models, Animal, Female, Glycoproteins, Male, Osteoporosis, Vascular Diseases, Bone Density, In Situ Hybridization, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Mice, Knockout, Gene Targeting, Mice, Osteoprotegerin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks